FDA Clears New Alzheimer’s Blood Test for People 55 and Older - WOWO News/Talk 92.3 FM and 1190 AM
The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.
How this was made
The 30-second read
Why it matters
The clearance could expand market access to Alzheimer’s diagnostics, benefit co‑developers, and open revenue streams for major lab service providers.
Market read
FDA clearance introduces a less invasive, widely accessible Alzheimer’s diagnostic, likely boosting stocks of the co‑developers and lab service providers.
What to watch
Reimbursement policy decisions and insurance coverage will be critical to the test's commercial success.
Background
The FDA cleared the Elecsys pTau217 plasma assay, the first single‑biomarker blood test for Alzheimer’s pathology, co‑developed by Roche Diagnostics and Eli Lilly.
Ticker impact
FDA clearance of Roche-Lilly pTau217 blood test may boost Eli Lilly's neurology portfolio and sales.
Potential modest upside of 3‑5% in the near term.
Regulatory approval is a material catalyst; Lilly co‑developed the assay and stands to benefit from increased test adoption.
Labcorp announced plans to offer the newly cleared pTau217 test through its network.
Modest upside of 1‑2% as the service rolls out.
Labcorp benefits from early adoption of a high‑demand diagnostic, but impact depends on uptake speed.
Quest Diagnostics will also provide the FDA‑cleared pTau217 assay to its customers.
Potential 1‑2% price lift.
Access to a novel test enhances Quest's specialty portfolio, though competitive dynamics moderate the effect.
Market effects
Strengthens the biotech diagnostics and neurology sectors, encouraging further R&D investment.
U.S. healthcare providers gain a less invasive Alzheimer’s test, potentially boosting domestic lab revenues.
Sets a precedent for blood‑based amyloid testing worldwide, influencing global pharma and diagnostics markets.
Counterpoint
Adoption may be slower than expected due to entrenched PET imaging reimbursement and physician inertia.
Key entities
- CompanyRoche Diagnostics
Swiss diagnostics firm co‑developer of the pTau217 test.
- CompanyEli Lilly
Pharmaceutical company co‑developer of the pTau217 assay.
- CompanyLabcorp
U.S. clinical laboratory network planning to offer the test.
- CompanyQuest Diagnostics
U.S. diagnostics company also planning test rollout.
